Senti Biosciences

62 articles about Senti Biosciences

• Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

  5/2/2023

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) today announced two oral presentations and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held May 16-20, 2023, in Los Angeles, CA.

• Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

  4/17/2023

  Senti Biosciences, Inc. today announced the presentation of preclinical data from multiple wholly-owned pipeline programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Florida.

• Senti Bio to Participate in Upcoming Investor Conferences - April 14, 2023

  4/14/2023

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced its participation at the following investor conferences.

• Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

  3/22/2023

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2022.

• Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

  3/14/2023

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, announced the acceptance of three abstracts for presentation at the American Association for Cancer Research Annual Meeting being held April 14-19, 2023, in Orlando, Florida.

• Senti Biosciences Announces New Employment Inducement Grants - February 03, 2023

  2/3/2023

  Senti Biosciences, Inc. announced that effective on February 1, 2023, the Compensation Committee of Senti Bio’s Board of Directors granted to 13 new employees stock options to purchase an aggregate of 309,000 shares of the Company’s common stock with a per share exercise price of $1.81.

• Senti Bio to Present at the SVB Securities Global Biopharma Conference

  2/1/2023

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, PhD, Senti’s Co-Founder and CEO, will present at the SVB Securities Global Biopharma Conference.

• Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

  1/27/2023

  Senti Biosciences, Inc. announced a strategic plan to focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to continue to pursue the development of Gene Circuits for other programs, including solid tumors.

• Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference

  12/19/2022

  Senti Biosciences, Inc. today announced that Tim Lu, MD, PhD, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 5:15 p.m. PT.

• Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

  12/11/2022

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, announced a presentation at the American Society of Hematology Annual Meeting in New Orleans.

• Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

  11/23/2022

  Senti Biosciences, Inc. will host an Investor Event on December 11 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

• Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

  11/10/2022

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today reported financial results for the third quarter ended September 30, 2022.

• Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

  11/3/2022

  Senti Biosciences, Inc. announced a poster presentation at the 64th American Society of Hematology Annual Meeting, being held December 10-13, 2022, in New Orleans, LA.

• Senti Bio Announces New Employment Inducement Grants - October 28, 2022

  10/28/2022

  Senti Biosciences, Inc. announced that on October 27, 2022, the compensation committee of Senti Bio’s board of directors granted to 9 new employees stock options to purchase an aggregate of 200,200 shares of the Company’s common stock with a per share exercise price of $2.39.

• 

  Synlogic’s CSO Outlines Risks and Opportunities in Emerging Synthetic Biotics Space

  10/5/2022

  Synlogic, Senti Biosciences and Novome are pioneering the field of synthetic biotics, which is so new there are only a handful of scientific articles using either that term or ‘engineered living therapeutics.

• Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

  10/5/2022

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, announced two poster presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting, being held November 10-12, 2022, in Boston, MA.

• Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference

  9/20/2022

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman, and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Chardan’s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, at 1:30 PM ET. Tim Lu will also participate in a panel on Gene Regulation on Tuesday, October 4, 2022, at 9:30 AM ET.

• Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference

  9/6/2022

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 4:05 p.m. ET.

• Senti Biosciences Announces New Employment Inducement Grants

  8/19/2022

  Senti Biosciences, Inc. announced that on August 18, 2022, the compensation committee of Senti Bio’s board of directors granted to thirty five new employees stock options to purchase an aggregate of 421,659 shares of the Company’s common stock with a per share exercise price of $1.99.

• Senti Bio Reports Second Quarter Financial Results and Business Updates

  8/15/2022

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), today reported financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments, including the selection of a lead development candidate from its SENTI-202 program with an anticipated Investigational New Drug (IND) application in 2023.